Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

NCT07162181 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell Lymphoma

Interventions

DRUG: Pirtobrutinib

Sponsor

Eli Lilly and Company